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Uneasy lies the head that wears a crown
William Shakespeare
despite their highbrow name, coronarvirus have proved eminently disruptive in recent 
years.1, 2 Since the epidemic of severe respiratory 
distress syndrome (SarS) due to the SarS-related 
coronavirus (SarS-CoV) infection and the Mid-
dle east respiratory syndrome (MerS) due to the 
MerS-related coronavirus (MerS-CoV), several 
experts could expect the advent of additional epi-
demics due to coronaviruses.3, 4 Yet, the ongoing 
pandemic of coronavirus-associated disease 2019 
(CoVid-2019) due to the infection from SarS-
CoV-2 (also known as 2019-nCoV) has wreaked 
havoc worldwide (Figure 1).5, 6 as italian citizens 
and cardiovascular practitioners, we are now fac-
ing this storm, with a mix of incredulity, fear, bold-
ness, and sense of duty.7-9 in addition, our unique 
editorial privileges urge us to summarize poignant 
facts on this global emergency, and provide some 
important insights for patients, practitioners, deci-
sion-makers, and researchers. an important pre-
amble to all the following discussed issues is the 
fact that information is accruing rapidly and some 
facts which may be considered correct and valid 
today may sooner or later be proved incomplete 
or incorrect.10, 11 Yet, we can clarify some known, 
unknown, and ensuing implications (Table i).
First, SarS-Cov-2 is a Betacoronavirus proba-
bly originating in chrysanthemum bats, with pan-
golins as intermediate hosts.5 it is characterized 
by glycosylated spike proteins which have high 
Figure 1.—Challenges of coronavirus-associated disease 
2019 (CoVid-2019). local infection cases of severe re-
spiratory distress syndrome-related coronavirus (SarS-
CoV-2) in a globalized world lead to global pandemic. after 
contagion, several risk factors may impact on patient risk 
of symptomatic and/or severe disease, with CoVid-2019 
typically beginning with fever, cough and dyspnea, with 
radiologic signs of pulmonary involvement. eventually, pa-
tient age and comorbidities mostly impact on prognosis and 
response to invasive mechanical ventilation, if needed. data 
science, big data, social media and other novel communica-
tion and analysis tools may help adopting effective popula-
tion measures and also streamline research efforts.
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asymptomatic carriers.16 Yet, symptomatic infec-
tions are relatively common, with a median pa-
tient age of 50-60 years, and range from cold-like 
symptoms, to cough, sore throat, fever, fatigue, 
myalgias, pneumonia, acute respiratory distress 
syndrome (ardS), multi-organ failure (MoF) 
and death. Worsening with dyspnea or other se-
vere features typically occurs between 5 and 10 
days after initial symptom onset.17 intriguingly, 
substantial variability and temporal differences 
between countries may be largely explained by 
numbers of diagnostic tests performed, pollution, 
and crowding, rather than on other factors, thus 
suggesting that most countries worldwide will 
face this substantial emergency.18
in terms of diagnosis, patients with moderate or 
severe symptoms typically display low lympho-
cyte counts, but high markers of systemic inflam-
mation, whereas features of atypical pneumonia 
are evident at chest X-rays and chest computed 
binding capacity toward angiotensin-converting 
enzyme 2 (aCe2) and employs the cellular trans-
membrane protease, serine 2 (TMPrSS2) for S 
protein priming expressed by lung cells.12, 13
it has spread initially in the Chinese city of 
Wuhan, Hubei province, being recognized first in 
december 2019, when forceful regional contain-
ment was exercised.14 despite this, after weeks, 
CoVid-19 cases were reported in several coun-
tries, and to date asymptomatic cases, symptom-
atic cases, deaths, and healed cases are reported 
in most countries worldwide. The virus is abun-
dant in infected people (with almost a billion 
rNa copies per ml of sputum), and can resist 
on contaminated objects for several hours or even 
days (including air exhaust outlets).15 it has a 
moderate incubation period (which can last up to 
20-24 days though), with a reproductive number 
(r0) greater than 2.5. Most infections are likely 
asymptomatic, and this leads to the potential of 
Table I.— Current known and unkown facts on coronavirus-associated disease 2019 (COVID-19), including impli-
cations for cardiovascular practitioners.
dimensions Known Unknow Cardiovascular implications
Biology CoVid-19 is caused by SarS-
Cov-2 a betacoronavirus 
which was first identified in 
late 2019 in China
Mode of transmission to humans 
from bats or other species is 
unclear
SarS-Cov-2 may directly impact on 
cardiovascular function, directly replicating 
and injury cells and tissues; indirect injury is 
also likely
epidemiology Highly contagious, incubation 
up to 24 days, latency up to 
10 days
The real extent of contagion remains 
unclear, but likely vast portions of 
untested populations are already 
infected and contagious
it is unclear whether SarS-CoV-2 infection has 
epidemiologic specificities in patients with or 
at risk of cardiovascular disease (e.g. those 
with atherothrombosis)
diagnosis dedicated rT-PCr test available 
but expensive and not with 
immediate results; Chest 
CT has a high sensitivity in 
epidemic areas; differential 
diagnosis with other 
cardiopulmonary conditions 
(e.g. aHF, PTe)
Point of care tests have limited 
precision and timeliness, and it 
is unclear whether routine quasi-
universal testing will be able to 
correctly identify infected people 
given incubation features
diagnosis of CoVid-19 may be complicated 
in patients with pre-existing cardiopulmonary 
disease, and the opposite is also true; other 
infectious and inflammatory conditions should 
not be disregarded as well, especially if SarS-
CoV-2 positivity turns out to be very prevalent
Prognosis Case fatality 1-5% or lower, 
several prognostic risk 
factors, ranging from age, 
smoking, elevated eSr, CrP, 
ldH, and chest CT features 
(opacifications, consolidations, 
thickening)
Precise and timely risk-
prognostication is not possible 
yet, nor is accurate appraisal of 
real case fatality including in the 
denominator all those infected but 
still asymptomatic
each individual and each patient under 
cardiovascular care may be already infected 
with SarS-CoV-2 or be at risk of being 
infected by healthcare personnel or other 
people
Management Supportive care, ranging 
from oxygen to mechanical 
ventilation and eCMo is 
beneficial in helping the 
patient clear the virus
Unclear role for aCei/arB in 
preventing or promoting infection; 
unclear role for remdesivir, 
lopinavir/ritonavir, interferon-
1β, chloroquine phosphate, 
intravenous immunoglobulin, 
MoaB or vaccines (if and when 
available)
Supportive care may by itself be associated 
with cardiac strain/injury; cardiovascular 
medications (e.g. anticoagulants) may interfere 
with supportive care; conflicting evidence 
for aCei/arB in preventing or promoting 
infection (recommendation is to maintain 
current therapy awaiting for additional studies)
aCei: angiotensin converting enzyme inhibitors; aHF: acute heart failure; arB: angiotensin receptor blockers; CrP: C-reactive protein; CT: 
computed tomography; eCMo: extracorporeal membrane oxygenation; eSr: erythrocyte sedimentation rate; ldH: lactate dehydrogenase; 
MoaB: monoclonal antibodies; PTe: pulmonary thromboembolism; rT-PCr: reverse-transcription polymerase chain reaction.
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ritonavir, interferon-1β, chloroquine phosphate, 
anakinra, baricitinib, ruxolitinib, fedratinib and 
intravenous immunoglobulin appear promising 
but controlled trials are needed before consider-
ing them on a large scale.23-25 Similarly, no vac-
cines are yet available, and several months will 
be needed to refine an effective and safe one.1
From a cardiovascular perspective, as physi-
cians we need to ensure we minimize our risk of 
contagion, and at the same time minimize the risk 
of transmitting the disease to other colleagues 
and patients.26 in addition, we must be aware 
that, given its increasing prevalence, CoVid-19 
enters the differential diagnosis of most cases of 
chest pain, dyspnea at rest, acute heart failure, 
arrhythmias, and non-ST-elevation myocardial 
infarction. indeed, SarS-CoV-2 has been found 
in cardiomyocytes in many series, it may cause 
myocarditis and myocardial injury, with eCg 
changes, sustained arrhythmias, left ventricular 
systolic dysfunction, and increase in troponins, 
and other markers of myocardial necrosis. in 
addition, CoVid-19 may resemble pulmonary 
thromboembolism and differential diagnostic 
clues need to be carefully sought. Therefore, 
we really need novel biomarkers to rapidly dis-
criminate CoVid-19 from the above-mentioned 
cardiovascular diseases. Moreover, hypoxemia is 
likely to lead to secondary myocardial injury, as 
is the typical proinflammatory milieu of ARDS 
and MoF. Finally, treatments used for severe 
CoVid-19, including chloroquine, vasopressors 
and mechanical ventilation, may also impact un-
favorably on cardiac function.
in conclusion, we hope the present piece of in-
formation will prove useful to inform concisely 
yet validly cardiovascular practitioners facing 
the SarS-CoV-2 pandemic. While containment 
and mitigation will benefit at large the manage-
ment of this emergency, and we need to comply 
duly to such measures as citizens,27 as practitio-
ners we will need to proactively diagnose, risk-
stratify and manage patients with CoVid-19, 
while not disregarding all other important car-
diovascular conditions, which may well be ne-
glected or worsened by this infectious disease. 
The hypothesis that inadequate management of 
this pandemic could lead to 60% of italians being 
infected and as many as 1 million deaths should 
tomography (CT), with frequent ground-glass 
infiltrates in the latter.19 risk-prognostication is 
difficult with COVID-19, as case fatality rate is 
heavily influenced by inaccuracies in measur-
ing asymptomatic infections, with a median age 
of deceased patients of 70-80 years.19, 20 indeed, 
since it is almost impossible to track the real 
number of infected subjects in the population, 
based on the fact that most of them have no or 
very few symptoms, it is very unlikely that we 
are able now to understand the real mortality rate 
of CoVid-19: we may indeed state that lack of 
evidence of transmission and disease is not evi-
dence of lack of transmission and disease. Yet, it 
seems that mortality ranges between 1% and 5% 
among symptomatic patients (with higher rates 
however in the very elderly). of note, although 
the mortality rate of SARS was significantly 
higher, both contagiousness and focus on frail of 
CoVid-19 make the overall death toll associated 
with this disease higher than that of SarS.14
Children appear completely spared by severe 
or fatal disease, whereas this may occur in adult 
patients of any age, even young and fit ones. Yet, 
most reports have shown that there is a clearly 
higher risk of severe infection (requiring non-in-
vasive ventilation, invasive ventilation, vasopres-
sors, extra-corporeal membrane oxygenation) or 
death in the elderly, those with one or more co-
morbidity, or even those with one or more cardio-
vascular risk factor (e.g. smoking history, hyper-
tension, obesity, diabetes mellitus).17, 19, 21 Nota-
bly, even apparently mild infections may lead to 
hospital admission and even ardS later on.19, 21 
early reports from the italian istituto Superiore di 
Sanità (iSS) on as many as 155 italian fatal cases 
of COVID-19 confirm the above findings.22 in 
particular, fever and dyspnea were very common, 
but cough, diarrhea and hemoptisis were also 
present occasionally. Median age of such cases 
was 81 years, with 69% men, and frequent co-
morbidities, including cardiovascular conditions 
such as hypertension and ischemic heart disease. 
Management to date is mainly supportive, simi-
lar to that of other infections causing atypical 
pneumonia, shock or MoF, with supportive care, 
oxygen supplementation, and the measures speci-
fied previously. Anecdotal reports on the poten-
tial usefulness of acyclovir, remdesivir, lopinavir/
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[internet] available from: http://www.quotidianosanita.it/sci-
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23. Colson P, rolain JM, lagier JC, Brouqui P, raoult d. Chlo-
roquine and hydroxychloroquine as available weapons to fight 
CoVid-19. int J antimicrob agents 2020 apr;55(4):105932. 
24. Chen l, Xiong J, Bao l, Shi Y. Convalescent plasma 
as a potential therapy for CoVid-19. lancet infect dis 
2020;20:398–400. 
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Smith d, et al. CoVid-19: combining antiviral and anti-in-
flammatory treatments. Lancet Infect Dis 2020;20:400–2. 
26. Zheng YY, Ma YT, Zhang JY, Xie X. CoVid-19 and the 
cardiovascular system. Nat rev Cardiol 2020. [epub ahead 
of print] 
27. gostin lo, Hodge Jg Jr. US emergency legal respons-
es to Novel Coronavirus: Balancing Public Health and Civil 
liberties. JaMa 2020. [epub ahead of print] 
28. liberoQuotidiano.it. Coronavirus, ricciardi: “Può es-
pandersi senza resistenze”. i modelli: possibile 1 milione 
di morti in italia; [internet] available from: https://www.
liberoquotidiano.it/news/italia/20895016/coronavirus_ric-
ciardi_modelli_italia_60_per_cento_contagiato_1_milione_
morti.html [cited 2020, Mar 9].
not scare us or push people toward negation,28 
but rather call for raised awareness, proactive 
measures, and multifaceted integrated interven-
tions to protect everyone, from our dear ones, to 
our patients and ourselves.
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